ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 59 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $4,934,000 | +82.3% | 1,774,915 | 0.0% | 0.03% | +63.2% |
| Q3 2019 | $2,707,000 | -26.7% | 1,774,915 | 0.0% | 0.02% | -29.6% |
| Q2 2019 | $3,692,000 | -41.6% | 1,774,915 | +0.5% | 0.03% | -43.8% |
| Q1 2019 | $6,320,000 | -6.5% | 1,765,415 | 0.0% | 0.05% | -21.3% |
| Q4 2018 | $6,761,000 | -60.4% | 1,765,415 | 0.0% | 0.06% | -57.3% |
| Q3 2018 | $17,054,000 | +93.2% | 1,765,415 | +0.0% | 0.14% | +74.4% |
| Q2 2018 | $8,827,000 | 0.0% | 1,765,315 | 0.0% | 0.08% | 0.0% |
| Q1 2018 | $8,827,000 | -1.0% | 1,765,315 | 0.0% | 0.08% | -3.5% |
| Q4 2017 | $8,915,000 | -33.2% | 1,765,315 | -0.2% | 0.08% | -41.4% |
| Q3 2017 | $13,349,000 | -30.0% | 1,768,891 | -66.6% | 0.14% | -35.3% |
| Q2 2017 | $19,062,000 | +10.8% | 5,294,945 | 0.0% | 0.22% | +2.8% |
| Q1 2017 | $17,209,000 | +32.7% | 5,294,945 | 0.0% | 0.22% | +21.1% |
| Q4 2016 | $12,972,000 | +648500.0% | 5,294,945 | +1058889.0% | 0.18% | – |
| Q3 2016 | $2,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 340,000 | $1,459,000 | 0.53% |
| RTW INVESTMENTS, LP | 4,733,323 | $20,306,000 | 0.31% |
| APIS CAPITAL ADVISORS, LLC | 70,000 | $300,000 | 0.29% |
| Hudson Bay Capital Management LP | 1,800,000 | $7,722,000 | 0.10% |
| COWEN AND COMPANY, LLC | 249,215 | $1,069,000 | 0.05% |
| Kerrisdale Advisers, LLC | 100,000 | $429,000 | 0.05% |
| Woodline Partners LP | 496,172 | $2,129,000 | 0.04% |
| Shay Capital LLC | 60,000 | $257,000 | 0.03% |
| Walleye Capital LLC | 231,037 | $991,000 | 0.03% |
| BOOTHBAY FUND MANAGEMENT, LLC | 212,700 | $912,000 | 0.02% |